GPx4 in the ferroptosis regulatory pathway: (a) GPx4 catalytic cycle representation

Role of GPx4 in the ferroptosis regulatory pathway: (a) GPx4 catalytic cycle representation. Under the reduction of lipid hydroperoxides (PLOOH) into their respective alcohols (PLOH), catalyzed by GPx4, GPx4 selenol (GPx4-SeH) is oxidized into selenic acid (GPx4-SeOH). Selenic acid is reduced to its active form, selenol, by a two-step reaction with GSH: The first GSH reacts with selenic acid to form a selenium–glutathione intermediate (GPx4-Se-SG), which is reduced by the second GSH to selenol. (b) Regulation of ferroptosis by GPx4. The conversion of polyunsaturated fatty acids (PUFAs) of phospholipids to peroxide PUFAs represents the initiation step to drive ferroptotic cell death. The phospholipid hydroperoxides (PE-OOH) are formed via non-enzymatic and enzymatic lipid peroxidation. The increased cytosolic labile iron pool (LIP) activates Fenton reactions and generates •OH radicals, which initiate non-enzymatic lipid peroxidation with the formation of PE-OOH, and their levels can be raised by 15-lipoxygenase (LOX) activity. GPx4 catalyzes the reduction of toxic PE-OOH into nontoxic alcohol, ultimately inhibiting ferroptosis. The amino acid antiporter system xc- (composed of SLC3A2 and SLC7A11 subunits) mediates the exchange of intracellular glutamate and extracellular cystine, which is converted into cysteine, contributing to GSH synthesis. Inhibition of the key enzyme of GSH synthesis—γGCL (buthionine sulfoximine, BSO)—and SLC7A11 (erastin, sulfasalazine, sorafenib) leads to the activation of ferroptosis through GSH depletion. A selenocysteine residue is added to the catalytic center of GPx4 with the use of isopentenyl pyrophosphate (IPP), leading to GPx4 activation and ferroptosis inhibition. IPP is generated via the mevalonate pathway: acetyl-CoA is converted to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). HMG-CoA is reduced by 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) to mevalonate, which, in turn, is converted to IPP. IPP also generates coenzymeQ10 (ubiquinone, CoQ10), which is reduced to ubiquinol by ferroptosis-suppressor-protein 1 (FSP1), blocking lipid peroxidation. The ferroptotic inducer FIN56 works through a dual mechanism of depleting GPX4 protein and CoQ10 levels
GPx4 in the ferroptosis regulatory pathway: (a) GPx4 catalytic cycle representation

Publication

Glutathione-Dependent Pathways in Cancer Cells (2024) Elena Kalinina, et al. Int J Mol Sci. 2024 Aug;25(15). Figure: F2.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates SLC3A2 SLC3A2 ncbigene_symbol SLC3A2 6520
Homo sapiens Primates SLC7A11 SLC7A11 ncbigene_symbol SLC7A11 23657
Homo sapiens Primates GPX-4 GPX-4 ncbigene_synonym GPX4 2879
Homo sapiens Primates GS GS famplex_relations GNAS 2778
Homo sapiens Primates GS GS famplex_relations GNAL 2774
Homo sapiens Primates HMGCR HMGCR ncbigene_symbol HMGCR 3156
Homo sapiens Primates LOX LOX ncbigene_symbol LOX 4015
Homo sapiens Primates IPP IPP ncbigene_symbol IPP 3652
Homo sapiens Primates FSP1 FSP1 ncbigene_synonym S100A4 6275
Homo sapiens Primates FSP1 FSP1 ncbigene_synonym ATL1 51062
Homo sapiens Primates FSP1 FSP1 ncbigene_synonym AIFM2 84883

Chemical mentions

Word Match MeSH Name ChEBI
Glu Glu 2-aminopentanedioic acid chebi:18237
sulfasalazine sulfasalazine 2-hydroxy-5-{[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid chebi:9334
sorafenib sorafenib 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide chebi:50924
Glu Glu 2-aminopentanedioic acid chebi:18237
GSH GSH L-gamma-glutamyl-L-cysteinylglycine chebi:16856
GSSG GSSG (2S,2'S)-5,5'-[disulfanediylbis({(2R)-3-[(carboxymethyl)amino]-3-oxopropane-1,2-diyl}imino)]bis(2-amino-5-oxopentanoic acid) chebi:17858
Glu Glu 2-aminopentanedioic acid chebi:18237
Cys Cys cysteine chebi:15356
GSH GSH L-gamma-glutamyl-L-cysteinylglycine chebi:16856
Gly Gly glycine chebi:15428
Acetyl-CoA acetyl-CoA 3'-phosphonatoadenosine 5'-(3-{(3R)-4-[(3-{[2-(acetylsulfanyl)ethyl]amino}-3-oxopropyl)amino]-3-hydroxy-2,2-dimethyl-4-oxobutyl} diphosphate) chebi:57288
HMG-CoA HMG-CoA 3'-phosphoadenosine 5'-{3-[(3R)-4-({3-[(2-{[(3S)-4-carboxy-3-hydroxy-3-methylbutanoyl]sulfanyl}ethyl)amino]-3-oxopropyl}amino)-3-hydroxy-2,2-dimethyl-4-oxobutyl] dihydrogen diphosphate} chebi:15467
GSH GSH L-gamma-glutamyl-L-cysteinylglycine chebi:16856
GSSG GSSG (2S,2'S)-5,5'-[disulfanediylbis({(2R)-3-[(carboxymethyl)amino]-3-oxopropane-1,2-diyl}imino)]bis(2-amino-5-oxopentanoic acid) chebi:17858
CoQ10 CoQ10 ubiquinone-10 chebi:46245
Ubiquinone ubiquinone ubiquinone-10 chebi:46245

Disease mentions

Word Match MeSH Name DOID